Pubblicazioni scientifiche

Santoni M.; Molina-Cerrillo J.; Myint Z.W.; Massari F.; Buchler T.; Buti S.; Matrana M.R.; De Giorgi U.; Rizzo M.; Zabalza I.O.; Galli L.; Zucali P.A.; Aurilio G.; Incorvaia L.; Bassanelli M.; Mammone G.; Salfi A.; Isella L.; Mollica V.; Grande E.; Porta C.; Battelli N., Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies, «TARGETED ONCOLOGY», 2022, 17, pp. 571 - 581 [Articolo in rivista]

Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Gadaleta-Caldarola G.; Montironi R.; Massari F., Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis, «FUTURE ONCOLOGY», 2022, 18, pp. 739 - 748 [Articolo in rivista]

Rizzo A.; Dadduzio V.; Ricci A.D.; Massari F.; Di Federico A.; Gadaleta-Caldarola G.; Brandi G., Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2022, 31, pp. 371 - 378 [Articolo in rivista]

Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; Santoni M.; Massari F., A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents, «ANTI-CANCER DRUGS», 2022, 33, pp. e43 - e51 [Articolo in rivista]

Rizzo A.; Mollica V.; Santoni M.; Massari F., Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: A meta-analysis, «IMMUNOTHERAPY», 2022, 14, pp. 617 - 625 [Articolo in rivista]

Santoni M.; Aurilio G.; Massari F.; Grande E.; Matrana M.R.; Rizzo M.; De Giorgi U.; Incorvaia L.; Martignetti A.; Molina-Cerrillo J.; Zabalza I.O.; Mollica V.; Rizzo A.; Battelli N.; Porta C., Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison, «CLINICAL GENITOURINARY CANCER», 2022, 20, pp. 285 - 295 [Articolo in rivista]

Rizzo A.; Mollica V.; Massari F., Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis, «EUROPEAN UROLOGY FOCUS», 2022, 8, pp. 152 - 159 [Articolo in rivista]

Nuvola G.; Rizzo A.; Mollica V.; Massari F., The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem?, «IMMUNOTHERAPY», 2022, 14, pp. 171 - 174 [Articolo in rivista]

Santoni M.; Molina-Cerrillo J.; Massari F.; Montironi R.; Grande E., Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study, «EUROPEAN UROLOGY», 2022, 81, pp. 623 - 624 [Articolo in rivista]

Santoni M.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Fragomeno B.; Battelli N.; Massari F., Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis, «EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH», 2022, 22, pp. 45 - 51 [Articolo in rivista]

Rizzo A.; Mollica V.; Santoni M.; Massari F., Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, pp. 1 - 3 [Articolo in rivista] Open Access

Rizzo A.; Mollica V.; Santoni M.; Palmiotti G.; Massari F., Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, pp. 1 - 8 [Articolo in rivista] Open Access

Rizzo A.; Mollica V.; Merler S.; Morelli F.; Sorgentoni G.; Oderda M.; Santoni M.; Massari F., Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2022, 18, pp. 235 - 240 [Articolo in rivista]

Viscardi G.; Tralongo A.C.; Massari F.; Lambertini M.; Mollica V.; Rizzo A.; Comito F.; Di Liello R.; Alfieri S.; Imbimbo M.; Della Corte C.M.; Morgillo F.; Simeon V.; Lo Russo G.; Proto C.; Prelaj A.; De Toma A.; Galli G.; Signorelli D.; Ciardiello F.; Remon J.; Chaput N.; Besse B.; de Braud F.; Garassino M.C.; Torri V.; Cinquini M.; Ferrara R., Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis, «EUROPEAN JOURNAL OF CANCER», 2022, 177, pp. 175 - 185 [Articolo in rivista]

Rebuzzi S.E.; Signori A.; Stellato M.; Santini D.; Maruzzo M.; De Giorgi U.; Pedrazzoli P.; Galli L.; Zucali P.A.; Fantinel E.; Carella C.; Procopio G.; Milella M.; Boccardo F.; Fratino L.; Sabbatini R.; Ricotta R.; Panni S.; Massari F.; Soraru M.; Santoni M.; Cortellini A.; Prati V.; Soto Parra H.; Atzori F.; Di Napoli M.; Caffo O.; Messina M.; Morelli F.; Prati G.; Nole F.; Vignani F.; Cavo A.; Roviello G.; Llaja Obispo M.A.; Porta C.; Buti S.; Fornarini G.; Banna G.L., The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis, «FRONTIERS IN ONCOLOGY», 2022, 12, pp. 1 - 15 [Articolo in rivista] Open Access

Rizzo A.; Mollica V.; Massari F., Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma, «JAMA ONCOLOGY», 2022, 8, pp. 783 - 784 [Articolo in rivista]

Pal S.K.; Uzzo R.; Karam J.A.; Master V.A.; Donskov F.; Suarez C.; Albiges L.; Rini B.; Tomita Y.; Kann A.G.; Procopio G.; Massari F.; Zibelman M.; Antonyan I.; Huseni M.; Basu D.; Ci B.; Leung W.; Khan O.; Dubey S.; Bex A., Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial, «THE LANCET», 2022, 400, pp. 1103 - 1116 [Articolo in rivista] Open Access

Brunelli M.; Martignoni G.; Malpeli G.; Volpe A.; Cima L.; Raspollini M.R.; Barbareschi M.; Tafuri A.; Masi G.; Barzon L.; Ammendola S.; Villanova M.; Cerruto M.A.; Milella M.; Buti S.; Bersanelli M.; Fornarini G.; Rebuzzi S.E.; Vellone V.G.; Gaggero G.; Procopio G.; Verzoni E.; Bracarda S.; Fanelli M.; Sabbatini R.; Passalacqua R.; Perrucci B.; Giganti M.O.; Donini M.; Panni S.; Tucci M.; Prati V.; Ortega C.; Calio A.; Eccher A.; Alongi F.; Pappagallo G.; Iacovelli R.; Mosca A.; Umari P.; Montagnani I.; Gobbo S.; Atzori F.; Munari E.; Maruzzo M.; Basso U.; Pierconti F.; Patriarca C.; Colombo P.; Lapini A.; Conti G.; Salvioni R.; Bollito E.; Cossarizza A.; Massari F.; Rizzo M.; Franco R.; Zito-Marino F.; Plata Y.A.; Galuppini F.; Sbaraglia M.; Fassan M.; Dei Tos A.P.; Colecchia M.; Moch H.; Scaltriti M.; Porta C.; Delahunt B.; Giannarini G.; Bortolus R.; Rescigno P.; Banna G.L.; Signori A.; Obispo M.A.L.; Perris R.; Antonelli A., Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study, «JOURNAL OF PERSONALIZED MEDICINE», 2022, 12, pp. 1 - 15 [Articolo in rivista] Open Access

Tassinari E.; Mollica V.; Nuvola G.; Marchetti A.; Massari F.; Rosellini M., Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy, «CANCER MANAGEMENT AND RESEARCH», 2022, 14, pp. 1945 - 1960 [Articolo in rivista] Open Access

Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F., Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw, «CURRENT ONCOLOGY», 2022, 29, pp. 1709 - 1722 [Articolo in rivista] Open Access